Our Science

We are harnessing innovations in multi-omic drug screening and cancer nanotechnology to develop a new class of synthetic lethality cancer therapeutics. 

scanMAX_HTS16_edited.jpg

Kinome Profile Mapping

lax_68832_elife-68832-fig2-v2.tif.jpg
shell.jpg

Transcriptomic RNA seq

Drug Screening

Micellar Nanocomplex

Drug Delivery Platform

Developing Transformative
Therapies for the Deadliest Cancers

Celestra Life Science is a preclinical-stage biotech startup formed by oncology leaders in academia and industry. We are committed to developing innovative medicines for the deadliest cancers.

Synthetic Lethality in RAS-activated Cancers

Our flagship drug CEL100 is a multi-kinase inhibitor that blocks key kinase effectors in all three major oncogenic pathways activated by RAS (RAF-MEK, PI3K-AKT, RalB-TBK1). CEL100 demonstrates robust single-agent activity in RAS-activated cancers across a wide diversity of tumor types and RAS alterations.

Panc-1.png

Pancreatic Ductal Adenocarcinoma

T24.png

Urinary Bladder Carcinoma

22RV1.png

Castration-Resistant Prostate Carcinoma

Our Team

1657891810693.jpg
IMG_3636 headshot.jpg
P53005-Mark-Lemmon.jpg
Co-Founder, President​
David Lu
MD-PhD Candidate,
Stanford School of Medicine
"Our Next Greatest Generation"
WIRED Magazine
Co-Founder, Chief Medical Officer
Ray Lee MD, PhD
Former Senior Director of Oncology,
Hoffman-La Roche
Former Director of Clinical Research,
Merck
Scientific Advisor​
Mark Lemmon PhD
Co-Director,
Yale Cancer Biology Institute
Alfred Gilman Professor of Pharmacology,
Yale School of Medicine
Collaborators & Partners at
stanford_medicine_logo.png
1200px-Yale_Cancer_Center.svg.png
image001.jpg